Improvement of asymmetric thyroid eye disease with teprotumumab

por Ugradar, Shoaib, Wang, Yao, Mester, Tunde, Kahaly, George J, Douglas, Raymond
Publicado 2022

Teprotumumab for thyroid eye disease: early response is not required for benefit

por Ugradar, Shoaib, Wang, Yao, Mester, Tunde, Kahaly, George J., Douglas, Raymond S.
Publicado 2021

TSH-Mediated TNFα Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist

por Chen, Hong, Shan, Shannon J. C., Mester, Tünde, Wei, Yi-Hsuan, Douglas, Raymond S.
Publicado 2015

CD40 Expression in Fibrocytes Is Induced by TSH: Potential Synergistic Immune Activation

por Mester, Tünde, Raychaudhuri, Nupur, Gillespie, Erin F., Chen, Hong, Smith, Terry J., Douglas, Raymond S.
Publicado 2016

CD34(−) Orbital Fibroblasts From Patients With Thyroid-Associated Ophthalmopathy Modulate TNF-α Expression in CD34(+) Fibroblasts and Fibrocytes

por Lu, Yan, Atkins, Stephen J., Fernando, Roshini, Trierweiler, Aaron, Mester, Tünde, Grisolia, Ana Beatriz Diniz, Mou, Pei, Novaes, Priscila, Smith, Terry J.
Publicado 2018